PD15 ‐ MP29‐02 effectively relieves both nasal and ocular symptoms in adolescents aged 12‐17 years: results from a meta‐analysis of 4 randomised controlled Seasonal Allergic Rhinitis (SAR) trials. (28th February 2014)